Detection of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cancer patients: Sharkia Governorate, Egypt

Clinical Laboratory

Volumn 57, Issue 5-6, 2011, Pages 363-371

  Mansour, Shymaa Abd El Azim ^a   Lotfy, Mohamed ^b   Omr, Ayman ^c  

^a ZAGAZIG UNIVERSITY   (Egypt)

^b ZAGAZIG UNIVERSITY HOSPITAL   (Egypt)

^c Fakous Cancer Centre   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT; VIRUS DNA;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CARCINOMA IN SITU; CONTROLLED STUDY; DNA EXTRACTION; EGYPT; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN TISSUE; HYSTERECTOMY; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PARITY; POLYMERASE CHAIN REACTION; PUNCH BIOPSY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING HABIT; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; WART VIRUS;

BIOPSY; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA PROBES, HPV; DNA, VIRAL; EGYPT; FEMALE; GENOTYPE; HUMANS; HYSTERECTOMY; NEOPLASM INVASIVENESS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PREVALENCE; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 79960440962     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Kondo K. Development of an HPV vaccine-remaining issues and perspective. Nippon Rinsho 2009;67(1):62-8.
2. http://apps.who.int/hpvcentre/statistics/dynamic/ico/ SummaryReportsSelect.cfm
3. Castellsagué X, Diaz M, de Sanjosé S, et al. Woldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006;98:303-15.
4. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine 2006;24(Suppl 3):S42-51.
5. Seoud MA, Seoud KM, Lindely S, Anis S. Human papilloma virus (HPV): Burden of the disease in cervical cancer in the Extended Middle East and North Africa (EMENA). A comprehensive review. J Clin Oncol 2009; 27:(2009 ASCO Annual Meeting Abstract No: e16577).
6. Sigurdsson K, Taddeo F, Benediktsdottir K, et al. HPV genotypes in CIN 2-3 lesions and cervical cancer: a population-based study. Int J Cancer 2007;121:2682-7. (Pubitemid 350136412)
7. Doorbar J. Papillomavirus life cycle organization and biomarker selection. Dis Markers 2007;23:297-313. (Pubitemid 47015790)
8. Schiffman MH, Brinton LA. The epidemiology of cervical carcinogenesis. Cancer 1995;76(10 Suppl):1888-1901.
9. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55(4):244-65. (Pubitemid 34293391)
10. Muñoz N, Castellsagué X, González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24(S3):S1-10.
11. el-All HS, Refaat A, Dandash K. Prevalence of cervical neoplastic lesions and Human Papilloma Virus infection in Egypt: National Cervical Cancer Screening Project. Infect Agent Cancer 2007;2:12.
12. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE. Human Papillomavirus Genotype Distributions: Implications for Vaccination and Cancer Screening in the United States. J Natl Cancer Inst 2009;101(7):475-87.
13. http://www.docstoc.com/docs/20261643/molecular-diagnostics-specimen- collection-and-transport.
14. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM. The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells 1989;7:209-14.
15. Nobre RJ, de Almeida LP, Martins TC. Complete genotyping of mucosal human papillomavirus using a restriction fragment length polymorphism analysis and an original typing algorithm. J Clin Virol 2008;42:13-21.
16. Monroy-Garcia A, Weiss-Steider B, Hernandez-Montes J, et al. Identification of two homologous antigenic peptides derived from L1HPV 16 and 18 proteins specific for the HLA B*3901 allele. Arch Virol 2002;147:1933-42. (Pubitemid 35218717)
17. Dören M. Assessing the effectiveness of human papillomavirus (HPV) vaccination to prevent cervical cancer: perspectives from Germany. J Epidemiol Community Health 2010;64:103-4.
18. Solis MT, Aguayo F, Vargas M, Olcay F, Puschel K, Corvalán A, Ferreccio C. Risk factors associated with abnormal cervical cytology among Chilean women: A case control study. Rev Med Chil 2010;138(2):174-80.
19. Weaver BA. Epidemiology and natural history of genital human papillomavirus infection. J Am Osteopath Assoc 2006;106:S2-8.
20. Schmeink CE, Massuger LF, Lenselink CH, Quint WG, Melchers WJ, Bekkers RL. Effect of the menstrual cycle and hormonal contraceptives on human papillomavirus detection in young, unscreened women. Obstet Gynecol 2010;116(1):67-75.
21. De Francesco MA, Gargiulo F, Schreiber C, Ciravolo G, Salinaro F, Manca, N. Detection and genotyping of human papillomavirus in cervical samples from Italian patients. J Med Virol 2005;75:588-92. (Pubitemid 40293527)
22. Ho GY, Studentsov, YY, Bieman R, Burk RD. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomark Prev 2004;13:110-6. (Pubitemid 38116628)
23. Ejeckam GC, Abdulla F, el-Sakka M, Dauleh W, Haseeb F. Gynaecological malignancies in Qatar. East Afr Med J 1994;71:777-81.
24. Prado JC, Calleja-Macias IE, Bernard HU, et al. Worldwide genomic diversity of the human papillomaviruses-53, 56, and 66, a group of high-risk HPVs unrelated to HPV-16 and HPV-18. Virology 2005;340(1):95-104. (Pubitemid 41191181)
25. Da Silva DM, Eiben GL, Fausch SC, et al. Cervical cancer vaccines: emerging concepts and developments. J Cell Physiol 2001;186:169-82. (Pubitemid 32041876)
26. Szostek S, Klimek M, Zawilinska B, and Kosz-Vnenchak M. Genotype-specific human papillomavirus detection in cervical smears. Acta Biochimica Polonica 2008;55(4):687-92.
27. Ho GY, Bierman R, Beardsley L, Chang CJ and Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8. (Pubitemid 28135669)
28. Odida M, de Sanjosé S, Quint W, Bosch XF, Klaustermeier J and Weiderpass E Human Papillomavirus type distribution in invasive cervical cancer in Uganda. BMC Infectious Diseases 2008;8:85.
29. Jastania R, Geddie WR, Chapman W, Boerner S.. Characteristics of apparently false-negative digene hybrid capture 2 high risk HPV DNA testing. Am J Clin Pathol 2006;125:223-8. (Pubitemid 43167163)
30. Lee SA, Kang D, Seo SS, et al. Multiple HPV infection in cervical cancer screened by HPVDNA Chip. Cancer Lett 2003;198:187-92. (Pubitemid 37303950)
31. Huang LW, Chao SL, Chen PH, Chou HP: Multiple HPV geno-types in cervical carcinomas: improved DNA detection and typing in archival tissues. J Clin Virol 2004;29:271-6.
32. Schwartz SM, Daling JR, Shera KA, et al: Human papillomavirus and prognosis of invasive cervical cancer: A population-based study. J Clin Oncol 2001;19:1906-15. (Pubitemid 32702534)